The CD46-JAG1 ligand-receptor interaction occurred in epithelial cells and endothelial cells was obvious in JAG1-positive group, which suggested that targeting CD46 in tumor cells may decrease the expression of JAG1, thereby reducing the immunosuppressive phenotype (Figure 7E). The gene discussed is JAG1; the disease is neoplasm.